A Phase I, Open Label Study in Healthy Subjects to Evaluate the Safety, Tolerability and Pharmacokinetics of Varying Oral Dosing Regimens for F901318
Phase of Trial: Phase I
Latest Information Update: 19 Feb 2018
At a glance
- Drugs F 901318 (Primary) ; Midazolam
- Indications Aspergillosis
- Focus Adverse reactions
- Sponsors F2G
- 13 Feb 2018 Planned End Date changed from 1 Mar 2018 to 1 Apr 2018.
- 13 Feb 2018 Planned primary completion date changed from 1 Mar 2018 to 1 Apr 2018.
- 13 Feb 2018 Status changed from not yet recruiting to recruiting.